HRT Patches Decision Important For Rural Women
Pharmac's decision to fund both Estradiol TDP Mylan and Estradot hormone replacement (HRT) patches is an important outcome for rural women, says Rural Women New Zealand (RWNZ).
'This is a meaningful decision for women, including many in rural areas, concerned about losing access to the menopause treatment that works best for them,' says National President Sandra Matthews.
'Every woman's experience of menopause is different. The initial decision to fund only one brand of patches left many women feeling unsupported and ignored. It is encouraging to see Pharmac listening to public feedback and responding with a more inclusive approach that restores choice to women managing menopause.'
It is slightly disappointing, however that due to ongoing supply constraints, Pharmac has not been able to extend dispensing quantities beyond monthly scripts.
'For rural women living far from pharmacies, accessing the patches they need monthly places a frequent burden on their time and travel,' says Matthews.
'We encourage Pharmac to keep working with suppliers to address these issues and improve equity of access for those in more remote parts of the country.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NZ Herald
15 hours ago
- NZ Herald
Pharmac makes U-turn and will fund Estradot and Mylan oestradiol patches from late 2025
Pharmac has made a funding U-turn and announced it will fund two brands of hormone replacement patches – Estradot and Estradiol TDP Mylan – from December. People will be able to use either brand of patch, subject to availability. Pharmac, the government agency that decides which medicines and related products
RNZ News
15 hours ago
- RNZ News
Pharmac to fund two oestrogen patches
Patients will be able to use either brand, "subject to availability". Photo: 123RF People who need oestrogen patches will have access to two brands free of charge from 1 December. Pharmac announced they had decided following consultation earlier this year to fund the oestradiol patches Estradot and Estradiol TDP Mylan. Patients will be able to use either brand, "subject to availability". Manager for pharmaceutical funding Adrienne Martin said the agency understood the importance for "people to have access to the treatment that works best for them". "We've heard very clearly from many people that while different brands of patches should work the same, this is not everyone's experience. "That's why we're funding two brands - so that people can access the oestradiol patches they need, depending on availability." From 1 December, the other currently funded brands of oestradiol patches will no longer be funded. The final decision followed a public backlash to Pharmac's decision in November to fund only the Mylan-brand, due to ongoing shortages of Estradot. More than 1300 people signed a petition calling on the government to keep the Estradot brand available on the basis the Mylan-brand was less effective in controlling menopausal symptoms. Martin said more than 1100 people responded to Pharmac's request for public feedback earlier this year. "We heard from people who wanted us to remove the patch limit and change the dispensing rules," said Martin. "We acknowledge how frustrating these limits are for people but changing or removing them would put pressure on demand, which would increase the risk of these patches not being available. "We will review the patch limit and dispensing rules in 12 months depending on the supply outlook." Pharmac would continue to monitor supply and work to ensure people can access the treatments they need, she said.
Scoop
16 hours ago
- Scoop
HRT Patches Decision Important For Rural Women
Pharmac's decision to fund both Estradiol TDP Mylan and Estradot hormone replacement (HRT) patches is an important outcome for rural women, says Rural Women New Zealand (RWNZ). 'This is a meaningful decision for women, including many in rural areas, concerned about losing access to the menopause treatment that works best for them,' says National President Sandra Matthews. 'Every woman's experience of menopause is different. The initial decision to fund only one brand of patches left many women feeling unsupported and ignored. It is encouraging to see Pharmac listening to public feedback and responding with a more inclusive approach that restores choice to women managing menopause.' It is slightly disappointing, however that due to ongoing supply constraints, Pharmac has not been able to extend dispensing quantities beyond monthly scripts. 'For rural women living far from pharmacies, accessing the patches they need monthly places a frequent burden on their time and travel,' says Matthews. 'We encourage Pharmac to keep working with suppliers to address these issues and improve equity of access for those in more remote parts of the country.'
